The US Food and Drug Administration (FDA) has approved Allergan’s drug-releasing implant, Durysta, for administration within the cavities of the eye to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Allergan
First CRISPR Study for Blindness to Start in the US This Fall
Patients are about to be enrolled in the first study to test a gene-editing technique known as CRISPR inside the body to try to cure an inherited form of blindness.
You must be logged in to post a comment.